ZAMBON SPA

🇮🇹Italy

Country: 🇮🇹Italy

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.zambon.com

Clinical Trials

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Phase 4

Completed

Conditions: Idiopathic Parkinson Disease

Interventions: Drug: Safinamide Methanesulfonate
Other: Safinamide methanesulfonate matching placebo

First Posted Date: 2019-02-15

Last Posted Date: 2023-05-22

Lead Sponsor: Zambon SpA

Target Recruit Count: 94

Registration Number: NCT03841604

Locations: 🇫🇷
CHU de GRENOBLE, Grenoble, France
🇫🇷
Hôpital Pierre-Paul Riquet, Toulouse, France
🇪🇸
Hospital del Mar, Barcelona, Spain

and more 42 locations

Safinamide for Multiple System Atrophy (MSA)

Phase 2

Completed

Conditions: Multiple System Atrophy

Interventions: Drug: Safinamide Methanesulfonate
Drug: Safinamide Methanesulfonate matching placebo

First Posted Date: 2018-11-27

Last Posted Date: 2021-10-13

Lead Sponsor: Zambon SpA

Target Recruit Count: 49

Registration Number: NCT03753763

Locations: 🇮🇹
Università di Bologna, Bologna, Italy
🇮🇹
Azienda Ospedaliera Universitaria - Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
🇮🇹
San Raffaele Cassino, Cassino, Italy

and more 16 locations

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

Phase 3

Active, not recruiting

Conditions: Bronchiolitis Obliterans
Chronic Rejection of Lung Transplant
Lung Transplant Rejection
Lung Transplant; Complications
Lung Transplant Failure and Rejection
Chronic Lung Allograft Dysfunction

Interventions: Drug: Liposomal Cyclosporine A
Drug: standard of care

First Posted Date: 2018-09-05

Last Posted Date: 2024-08-02

Lead Sponsor: Zambon SpA

Target Recruit Count: 220

Registration Number: NCT03657342

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
Baylor St. Luke's Medical Center, Houston, Texas, United States

and more 33 locations

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)

Phase 3

Active, not recruiting

Conditions: Chronic Rejection of Lung Transplant
Lung Transplant Rejection
Lung Transplant; Complications
Lung Transplant Failure and Rejection
Chronic Lung Allograft Dysfunction
Bronchiolitis Obliterans

Interventions: Drug: Liposomal Cyclosporine A
Drug: Standard of Care

First Posted Date: 2018-09-04

Last Posted Date: 2024-08-02

Lead Sponsor: Zambon SpA

Target Recruit Count: 220

Registration Number: NCT03656926

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University Hospital, Baltimore, Maryland, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States

and more 36 locations

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

Phase 3

Terminated

Conditions: Non Cystic Fibrosis Bronchiectasis

Interventions: Drug: CMS
Other: Placebo

First Posted Date: 2018-03-09

Last Posted Date: 2023-12-29

Lead Sponsor: Zambon SpA

Target Recruit Count: 287

Registration Number: NCT03460704

Locations: 🇫🇷
Zambon investigative site, Reims, France
🇺🇸
ZambonInvestigative Site, Abingdon, Virginia, United States
🇵🇹
Zambon Investigative Site, Lisboa, Portugal

and more 2 locations

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)

Phase 3

Completed

Conditions: Non Cystic Fibrosis Bronchiectasis

Interventions: Drug: CMS
Other: Placebo

First Posted Date: 2017-03-28

Last Posted Date: 2023-11-15

Lead Sponsor: Zambon SpA

Target Recruit Count: 377

Registration Number: NCT03093974

Locations: 🇬🇧
Zambon investigative Site, Manchester, United Kingdom
🇬🇧
Zambon Investigative site, Dundee, United Kingdom
🇬🇧
Zambon Investigational site, Liverpool, United Kingdom

and more 2 locations

Efficacy and Tolerability Study of ZP-025 Vaginal Gel for the Treatment of Vaginal Dryness

Not Applicable

Completed

Conditions: Vaginal Dryness

Interventions: Device: Vaginal gel, Medical Device Class 2A

First Posted Date: 2016-12-15

Last Posted Date: 2017-06-28

Lead Sponsor: Zambon SpA

Target Recruit Count: 121

Registration Number: NCT02994342

Locations: 🇮🇹
Ospedale San Giovanni di Dio, Cagliari, Italy
🇮🇹
Policlinico Careggi, Firenze, Italy
🇮🇹
Clinica Macedonio Melloni, Milano, Italy

and more 3 locations

Clinical Study to Evaluate Z7200 Pharmacokinetics Profile

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Z7200 without oral activated charcoal
Drug: Symbicort Turbohaler without oral activated charcoal
Drug: Z7200 with oral activated charcoal
Drug: Symbicort Turbohaler with oral activated charcoal

First Posted Date: 2015-12-16

Last Posted Date: 2022-02-23

Lead Sponsor: Zambon SpA

Target Recruit Count: 91

Registration Number: NCT02631941

Locations: 🇬🇧
Quotient Clinical Ltd, Ruddington, United Kingdom

Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Diclofenac sodium and safinamide
Drug: Diclofenac sodium

First Posted Date: 2015-07-13

Last Posted Date: 2016-04-15

Lead Sponsor: Zambon SpA

Target Recruit Count: 24

Registration Number: NCT02495831

Locations: 🇨🇭
Cross Research SA, Phase I Unit, Arzo, Ticino, Switzerland

Bioequivalence Study of Two Different Formulations of N-acetyl-cysteine (NAC)

Phase 1

Completed

Conditions: no Condition

Interventions: Drug: N-acetylcysteine

First Posted Date: 2014-10-15

Last Posted Date: 2021-11-05

Lead Sponsor: Zambon SpA

Target Recruit Count: 48

Registration Number: NCT02265224

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy